Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Peter Gale

Showing results (161-170 of 557) with videos related to

Pageof 56
Sort By:
Leukemia|June 25, 2024
Is there really an accelerated phase of chronic myeloid leukaemia?Robert Peter Gale, Qian Jiang, Jane F Apperley, et al.
Biomolecular Detection and Quantification|March 24, 2017
Molecular techniques for the personalised management of patients with chronic myeloid leukaemiaMary Alikian, Robert Peter Gale, Jane F Apperley, et al.
Journal of Cancer Research and Clinical Oncology|March 3, 2017
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapyQian Jiang, Hai-Bo Wang, Lu Yu, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2026
Why are we still using cisplatin? : Rationale for the continued use of cisplatin in oncologyJemma Arakelyan, Herbert Loong, Robert Peter Gale, et al.
Leukemia|June 12, 2021
NK-/T-cell lymphomasHua Wang, Bi-Bo Fu, Robert Peter Gale, et al.
Bone Marrow Transplantation|March 28, 2019
Causal inference in randomized clinical trialsCheng Zheng, Ran Dai, Robert Peter Gale, et al.
Leukemia|January 22, 2026
Prognostic value of anemia plus thrombocytopenia in primary myelofibrosisGiovanni Barosi, Annalisa De Silvestri, Robert Peter Gale, et al.
Bone Marrow Transplantation|April 14, 2026
Blood cell-derived transplants at 40Anthony D Ho, Peter Dreger, Christopher Juttner, et al.
Leukemia|June 1, 2024
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemiaYingqi Shao, Neil E Kay, Robert Peter Gale, et al.
Leukemia Research|September 2, 2014
Why is there so much therapy-related AML and MDS and so little therapy-related CML?Robert Peter Gale, Lynn Hlatky, Rainer K Sachs, et al.
Pageof 56

Showing results (161-170 of 557) with videos related to

Sort By:
Pageof 56
Leukemia|June 25, 2024
Is there really an accelerated phase of chronic myeloid leukaemia?Robert Peter Gale, Qian Jiang, Jane F Apperley, et al.
Biomolecular Detection and Quantification|March 24, 2017
Molecular techniques for the personalised management of patients with chronic myeloid leukaemiaMary Alikian, Robert Peter Gale, Jane F Apperley, et al.
Journal of Cancer Research and Clinical Oncology|March 3, 2017
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapyQian Jiang, Hai-Bo Wang, Lu Yu, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2026
Why are we still using cisplatin? : Rationale for the continued use of cisplatin in oncologyJemma Arakelyan, Herbert Loong, Robert Peter Gale, et al.
Leukemia|June 12, 2021
NK-/T-cell lymphomasHua Wang, Bi-Bo Fu, Robert Peter Gale, et al.
Bone Marrow Transplantation|March 28, 2019
Causal inference in randomized clinical trialsCheng Zheng, Ran Dai, Robert Peter Gale, et al.
Leukemia|January 22, 2026
Prognostic value of anemia plus thrombocytopenia in primary myelofibrosisGiovanni Barosi, Annalisa De Silvestri, Robert Peter Gale, et al.
Bone Marrow Transplantation|April 14, 2026
Blood cell-derived transplants at 40Anthony D Ho, Peter Dreger, Christopher Juttner, et al.
Leukemia|June 1, 2024
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemiaYingqi Shao, Neil E Kay, Robert Peter Gale, et al.
Leukemia Research|September 2, 2014
Why is there so much therapy-related AML and MDS and so little therapy-related CML?Robert Peter Gale, Lynn Hlatky, Rainer K Sachs, et al.
Pageof 56